Compulsory licensing policy implementation in Thailand
Files
Publisher
Issued Date
2014
Issued Date (B.E.)
2557
Available Date
Copyright Date
Resource Type
Series
Edition
Language
eng
File Type
application/pdf
No. of Pages/File Size
231 leaves
ISBN
ISSN
eISSN
Other identifier(s)
b185150
Identifier(s)
Access Rights
Access Status
Rights
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Rights Holder(s)
Physical Location
National Institute of Development Administration. Library and Information Center
Bibliographic Citation
Citation
Tapanee Phueksuwan (2014). Compulsory licensing policy implementation in Thailand. Retrieved from: http://repository.nida.ac.th/handle/662723737/3093.
Title
Compulsory licensing policy implementation in Thailand
Alternative Title(s)
Author(s)
Advisor(s)
Editor(s)
item.page.dc.contrubutor.advisor
Advisor's email
Contributor(s)
Contributor(s)
Abstract
The objectives of this research were to investigate the following: 1) the
reasons and needs for the compulsory licensing policy in Thailand, 2) the guidelines
for implementing the policy in Thailand, 3) the factors that affect compliance with the
policy in Thailand, and 4) patients’ effective access to drugs as a result of the policy
in Thailand. This research involved principals and concepts about public policy, as
well as concepts about drug patents and compulsory licensing. The focus was on the
reasons and needs for compulsory licensing, costs of production or importation of
generic drugs for sale under the policy, guidelines and results of the policy
implementation, as well as factors that have affected the policy implementation in
Thailand. This research relied on mixed methods-qualitative methods and quantitative
methods. Qualitative data were studied to explore answers to the research questions,
based on secondary data and primary data by means of in-depth face-to-face and
phone interviews. The interviewees included policy makers at the Ministry of Public
Health (MOPH) and policy-implementing personnel-directors from government
hospitals affiliated with the the Ministry of Public Health (MOPH) and universities.
Out of 45 government hospitals, twenty hospital directors (representing 44.44%) gave
their consent to the interviews. Quantitative data were used to confirm the study
results of the evaluation of the policy implementation; such data included the number
of new patients receiving the drugs and the savings in costs from 2008 to 2010.
The study results led to the conclusion that the compulsory licensing policy
can definitely solve the problem of patients’ inaccessibility to drugs. From 2008 to
2010, the amount of each drug administered to new patients increased continually,
and the drug costs fell steadily by approximately two billion baht. As for the policy
implementation guidelines, the Ministry of Public Health (MOPH) formulated
protocol guidelines as the MOPH’s Notification for each drug. However, the
performance of individual hospitals depended on their characteristics, which were
different in many aspects-the roles of directors in the hospital, the roles of doctors in
the hospital, and characteristics of the hospital.
Factors that affected the success in the policy implementation at the macro and
micro levels covered the clarity of the policy, the consistency between the policy and
the problem, budgets, and political changes. Factors that were related to the failure in
the policy implementation included lack of communication of the policy, characteristics
of respective hospitals, attitudes of practitioners, and political changes.
The study on these success and failure factors reflected the drawbacks of the
policy implementation at both levels. They included: 1) lack of a strict, clear drugpricing
control mechanism that differentiates drugs from other commercial goods, 2)
lack of knowledge about the evaluation of “innovative” drugs being applied for a
patent before granting it to them, 3) the Ministry of Public Health’s lack of campaigns
for boosting knowledge and understanding about patients’ rights in the public health
system, the compulsory licensing policy, or generic and original drugs in terms of
their efficiency, effectiveness, costs, quality and toxicology for the general public,
patients, doctors and medical personnel; and its lack of surveys of government
hospitals to determine how different they were with respect to preparedness,
equipment, and equality in factors prior to the implementation of this policy, 4) the
Ministry of Public Health’s lack of clarification about legal mechanisms available to
minimize the impacts from the allegations about intellectual property infringement by
people who lost some benefits from this policy, 5) unequal medical care benefits
among patients in different public health care schemes, 6) the Government
Pharmaceutical Organization (GPO)’s need for building the faith and confidence that
its production of generic drugs meets established standards, that the importation
process of generic drugs is transparent, and that the quality and effectiveness of the
imported generic drugs are equivalent to those of original drugs,
The Thai government and the Ministry of Public Health (MOPH) need to cope
with the identified deficiencies and improve their performance in order to result in
efficient policy implementation and solve the problem of patients’ inaccessibility to
drugs as a whole.
Table of contents
Description
Dissertation (D.P.A.)--National Institute of Development Administration, 2014.